April 2, 2020 Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19 Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19.
Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19